Image of an eye
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

PYC Therapeutics Ltd (ASX:PYC) has announced that the US Food and Drug Administration (FDA) has granted ‘Rare Pediatric Disease (RPD)’ designation to its development program for a drug aimed at treating patients with blinding eye disease Autosomal Dominant Optic Atrophy (ADOA).

Earlier this month, PYC said it had received regulatory approval to begin human trials for the drug – PYC-001 – involving individuals with ADOA, with a Phase 1 Single Ascending Dose study to begin imminently.

ADOA – which affects 1 one every 35,000 people – is a condition which begins in childhood and ultimately leads to legal blindness by middle age among most patients, being caused by insufficient expression of the OPA1 gene in the retina.

Additionally, there are no current treatment options for patients with ADOA, although the market to address this condition is estimated at more than $2 billion per year.

The designation received by the FDA is focused on treatments of OPA1-associated
vision loss, and its Rare Pediatric Disease program aims to incentivise drug development for serious and rare diseases affecting children.

Receiving this status means that PYC will be eligible to receive a Priority Review Voucher (PRV) which can be redeemed to receive priority review for a different product or sold to another sponsor.

PYC shares have risen on the news. At 12:34 AEST, they were trading at 13.5 cents: a rise of 3.85% since the market opened.

PYC by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse closes flat after Min Res AGM | November 21, 2024

Besieged Mineral Resources (ASX:MIN) Managing Director Chris Ellison told its AGM he deeply regrets his dodgy…
Man holding health IT icon

Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech

Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision…
Two Symal Group workers.

Quiet day one for Symal Group but slow ASX start no real surprise

Civil construction company Symal Group (ASX:SYL) had a relatively quiet first day after
Confused reader

MinRes’s Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing,…